Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Open label, single arm, multi-centre study of pembrolizumab following trans-arterial
chemoembolization (TACE). Twenty-six to 32 evaluable participants with primary liver cancer
(hepatocellular cancer; HCC) will be assessed. The primary objective is to determine the
safety and tolerability of pembrolizumab following TACE. The secondary objective is to
evaluate the efficacy of pembrolizumab following TACE by improving progression-free survival
rates as measured by modified response evaluation criteria in solid tumours (mRECIST)
criteria.